Successful treatment of a 19-year-old patient with locally advanced clear cell adenocarcinoma of the uterine cervix using recombinant human adenovirus type 5 (Oncorine) combined with chemoradiotherapy: a case report

Clear cell adenocarcinoma (CCAC) of the uterine cervix is a rare histological subtype of cervical cancer. The optimal treatment paradigm for this tumor has not yet been established. In recent years, oncolytic viruses have become a promising strategy for cancer treatment. However, the role of oncolytic viruses in treating CCAC of the uterine cervix is unclear. We report a case study of a 19-year-old woman with locally advanced CCAC of the uterine cervix. The patient was first treated with external beam radiation therapy (50 Gy/25 f) and chemotherapy (cisplatin, 40 mg/m(2)/week, 5 weeks) with only slight reduction of the cervical tumor (45 mm × 34 mm × 51 mm). After receiving one cycle of intratumor injection therapy of Oncorine (5.0×10(11) virus particles daily, from day 1 to day 5), her cervical tumor was dramatically reduced (29 mm × 26 mm × 24 mm). Subsequently, the patient received two cycles of intratumor injection therapy of Oncorine combined with brachytherapy (7 fractions) and chemotherapy (cisplatin and paclitaxel). No serious adverse events occurred during treatment. The results at the 7-month follow-up showed that the patient achieved complete response. Our case was a successful exploration of Oncorine in the treatment of locally advanced CCAC of the uterine cervix, which supports the use of oncolytic viruses as a promising treatment option for young women with this tumor.